A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Summary
Third Opinion Trial Synopsis:
Doctors are doing a study to see if a new medicine called ruxolitinib, along with steroids and lenalidomide, can help people with a certain type of cancer called multiple myeloma that is getting worse. They want to make sure it is safe and works well.
Doctors are doing a study to see if a new medicine called ruxolitinib, along with steroids and lenalidomide, can help people with a certain type of cancer called multiple myeloma that is getting worse. They want to make sure it is safe and works well.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: